Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
David M. Goldenberg(Immunomedics (United States)), Robert M. Sharkey(Immunomedics (United States))
Cited by 464
Related Papers
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
|Oncotarget|2018|306
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
|BMC Cancer|2007|273
Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement
|British Journal of Cancer|2010|52